Novel B7-H3-targeted drug significantly improved progression-free survival versus chemothe ...

The antibody-drug conjugate risvutatug rezetecan could be a major advance for patients with relapsed or refractory ...

An integrative analysis finds the splicing protein LSM5 over-expressed across cancers and linked to cell-cycle progression, ...

A research team at Johns Hopkins Medicine has created and trained a machine learning model to calculate percent necrosis (PN)—or, what percentage of a tumor is "dead" and no longer active—in patients ...

The osteosarcoma treatment pipeline is gradually expanding, with emerging therapies such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk; SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug ...

A case report from Warsaw describes the first documented second reirradiation with stereotactic body radiotherapy in ...

Scientists co-led by St. Jude Children's Research Hospital have identified a potential therapeutic vulnerability in some ...

The strangely named hedgehog pathway that's crucial to bone growth has emerged as a key in the fight to treat the bone cancer osteosarcoma. Osteosarcoma is a type of bone cancer that primarily affects ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

Osteosarcoma remains one of the most aggressive primary malignant bone tumor, despite all the treatment options available, there has been little progress in osteosarcoma treatment in children and ...

Charlotte swam in a private Los Angeles pool after her owner’s request for one more day in the water was answered. The outing ...